{"drugs":["Insulin Degludec"],"mono":{"0":{"id":"930443-s-0","title":"Generic Names","mono":"Insulin Degludec"},"1":{"id":"930443-s-1","title":"Dosing and Indications","sub":{"0":{"id":"930443-s-1-4","title":"Adult Dosing","mono":"<ul><li>insulin degludec has centralized marketing authorization by the European Medicines Agency for use in the European Union for the treatment of diabetes mellitus in adults<\/li><li>insulin degludec is available in strengths of 100 units\/mL and 200 units\/mL; delivery device counters display number of units regardless of strength; dose conversion between strengths is not necessary<\/li><li>1 unit of insulin degludec corresponds with 1 international unit of human insulin, 1 unit of insulin glargine, or 1 unit of insulin detemir<\/li><li>safety and efficacy have not been established in patients younger than 18 years<\/li><li><b>Type 1 diabetes mellitus:<\/b> administer SUBQ once daily, preferably at the same time every day; use with mealtime insulin; individualize dose based on fasting plasma glucose levels (European Medicines Agency approved dosing)<\/li><li><b>Type 2 diabetes mellitus:<\/b> initial, 10 units SUBQ once daily, preferably at the same time every day; individualize dose based on fasting plasma glucose levels (European Medicines Agency approved dosing).<\/li><\/ul>"},"3":{"id":"930443-s-1-7","title":"Indications","mono":"<b>Non-FDA Labeled Indications<\/b><ul><li>Type 1 diabetes mellitus<\/li><li>Type 2 diabetes mellitus<\/li><\/ul>"}}},"3":{"id":"930443-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930443-s-3-9","title":"Contraindications","mono":"hypersensitivity to insulin degludec or any product component <br\/>"},{"id":"930443-s-3-10","title":"Precautions","mono":"<ul><li>adrenal, pituitary, or thyroid disease; increased risk of hypoglycemia; dose adjustment may be necessary<\/li><li>alcohol consumption; may intensify or reduce effect of insulin<\/li><li>cardiac failure has been reported with concomitant pioglitazone use; increased risk in patients with preexisting cardiac risk factors; monitoring recommended; treatment discontinuation of pioglitazone may be required<\/li><li>change in diet or physical activity; increased risk of hypoglycemia; monitoring and dose adjustment may be necessary<\/li><li>change in insulin type, brand, or manufacturer; dose adjustment may be necessary<\/li><li>diabetic retinopathy; abrupt improvement in glycemic control may lead to temporary worsening of condition<\/li><li>elderly patients; intensified blood glucose monitoring recommended; dose adjustment may be required<\/li><li>hepatic disease; intensified blood glucose monitoring recommended; dose adjustment may be required<\/li><li>hyperglycemia with potential progression to diabetic ketoacidosis may occur, especially in patients with type 1 diabetes; treatment for severe cases or dose adjustment may be required<\/li><li>hypoglycemia has been reported; usual warning symptoms may be altered in patients with long-term disease or greatly improved glucose control; dose adjustment may be necessary<\/li><li>illness, infection, or fever; increased risk of hypo- or hyperglycemia; dose adjustment may be necessary<\/li><li>insulin antibody formation may occur; increased risk of hyper- or hypoglycemia; dose adjustment may be required<\/li><li>IV or IM use and use in insulin pumps not recommended<\/li><li>pregnancy; intensified blood glucose control and monitoring recommended when considering pregnancy and during gestation<\/li><li>renal disease; intensified blood glucose monitoring recommended; dose adjustment may be required<\/li><\/ul>"},{"id":"930443-s-3-11","title":"Pregnancy Category","mono":"Unknown<br\/>"},{"id":"930443-s-3-12","title":"Breast Feeding","mono":"Unknown<br\/>"}]},"4":{"id":"930443-s-4","title":"Drug Interactions","sub":{"1":{"id":"930443-s-4-14","title":"Major","mono":"<ul><li>Amisulpride (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Asenapine (theoretical)<\/li><li>Atazanavir (theoretical)<\/li><li>Balofloxacin (theoretical)<\/li><li>Besifloxacin (theoretical)<\/li><li>Ciprofloxacin (theoretical)<\/li><li>Clozapine (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Enoxacin (theoretical)<\/li><li>Ethylestrenol (theoretical)<\/li><li>Fleroxacin (theoretical)<\/li><li>Flumequine (theoretical)<\/li><li>Fosamprenavir (theoretical)<\/li><li>Gatifloxacin (theoretical)<\/li><li>Gemifloxacin (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Indinavir (theoretical)<\/li><li>Lanreotide (theoretical)<\/li><li>Levofloxacin (theoretical)<\/li><li>Liraglutide (theoretical)<\/li><li>Lomefloxacin (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Lurasidone (theoretical)<\/li><li>Mesterolone (theoretical)<\/li><li>Methandriol (theoretical)<\/li><li>Methandrostenolone (theoretical)<\/li><li>Methenolone (theoretical)<\/li><li>Metreleptin (established)<\/li><li>Mibolerone (theoretical)<\/li><li>Moxifloxacin (theoretical)<\/li><li>Nadifloxacin (theoretical)<\/li><li>Nandrolone (theoretical)<\/li><li>Nelfinavir (theoretical)<\/li><li>Norfloxacin (theoretical)<\/li><li>Octreotide (theoretical)<\/li><li>Ofloxacin (theoretical)<\/li><li>Olanzapine (theoretical)<\/li><li>Oxandrolone (theoretical)<\/li><li>Oxymetholone (theoretical)<\/li><li>Paliperidone (theoretical)<\/li><li>Pasireotide (theoretical)<\/li><li>Pazufloxacin (theoretical)<\/li><li>Pefloxacin (theoretical)<\/li><li>Pioglitazone (theoretical)<\/li><li>Pramlintide (established)<\/li><li>Prulifloxacin (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Risperidone (theoretical)<\/li><li>Ritonavir (theoretical)<\/li><li>Rosiglitazone (theoretical)<\/li><li>Rufloxacin (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Sertindole (theoretical)<\/li><li>Sparfloxacin (theoretical)<\/li><li>Stanozolol (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Tipranavir (theoretical)<\/li><li>Tosufloxacin (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><li>Zotepine (theoretical)<\/li><\/ul>"},"2":{"id":"930443-s-4-15","title":"Moderate","mono":"<ul><li>Acebutolol (probable)<\/li><li>Albiglutide (probable)<\/li><li>Atenolol (probable)<\/li><li>Betaxolol (probable)<\/li><li>Bisoprolol (probable)<\/li><li>Carteolol (probable)<\/li><li>Carvedilol (probable)<\/li><li>Celiprolol (probable)<\/li><li>Dulaglutide (probable)<\/li><li>Esmolol (probable)<\/li><li>Exenatide (probable)<\/li><li>Furazolidone (probable)<\/li><li>Iproniazid (probable)<\/li><li>Isocarboxazid (probable)<\/li><li>Labetalol (probable)<\/li><li>Levobunolol (probable)<\/li><li>Linezolid (probable)<\/li><li>Lixisenatide (probable)<\/li><li>Methylene Blue (probable)<\/li><li>Metipranolol (probable)<\/li><li>Metoprolol (probable)<\/li><li>Moclobemide (probable)<\/li><li>Nadolol (probable)<\/li><li>Nebivolol (probable)<\/li><li>Nialamide (probable)<\/li><li>Oxprenolol (probable)<\/li><li>Penbutolol (probable)<\/li><li>Phenelzine (probable)<\/li><li>Pindolol (probable)<\/li><li>Practolol (probable)<\/li><li>Procarbazine (probable)<\/li><li>Propranolol (probable)<\/li><li>Rasagiline (probable)<\/li><li>Selegiline (probable)<\/li><li>Sotalol (probable)<\/li><li>Timolol (probable)<\/li><li>Tranylcypromine (probable)<\/li><\/ul>"}}},"5":{"id":"930443-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Dermatologic:<\/b>Injection site reaction (1% to less than 10%)<br\/><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Heart failure<\/li><li><b>Endocrine metabolic:<\/b>Hyperglycemia, Hypoglycemia (10% or more)<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction (0.01% to less than 0.1%)<\/li><\/ul>"},"6":{"id":"930443-s-6","title":"Drug Name Info","sub":{"2":{"id":"930443-s-6-19","title":"Class","mono":"<ul><li>Antidiabetic<\/li><li>Insulin, Long Acting<\/li><\/ul>"},"3":{"id":"930443-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"9":{"id":"930443-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>not for IV or IM use or for use in insulin infusion pumps<br\/><\/li><li><b>Subcutaneous<\/b><br\/><ul><li>administer subQ by injection into the upper arm, thigh, or abdominal wall<\/li><li>rotate injection sites within same region<\/li><li>use within 8 weeks of opening; do not refrigerate after opening<\/li><li>do not share insulin pens or cartridges among patients because of the risk of transmission of hepatitis viruses, HIV, or other bloodborne pathogens; use of a new disposable pen needle does not mitigate risks<\/li><li>a flexible dosing schedule is allowed; however, allow at least 8 hours between injections<\/li><\/ul><\/li><\/ul>"}}}